Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Isatuximab plus lenalidomide-dexamethasone versus lenalidomide-dexamethasone in elderly patients with newly diagnosed multiple myeloma
2024-515581-13-00Phase 2Authorised
- Sponsor
- Arbeitsgemeinschaft medikamentoese Tumortherapie
- Start
- Oct 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 3
01
Overview
Phase 2, randomised, open-label trial of isatuximab in multiple myeloma (MM) (2 arms), sponsored by Arbeitsgemeinschaft medikamentoese Tumortherapie. Primary endpoint: MRD negativity after end of induction. Planned start Oct 2021; status: authorised.
02
Drugs
isatuximab
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on 2024-515581-13-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-515581-13-00.